Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Dukes

Clinical Cardiac Electrophysiology Ventura, CA Medical Doctor

NPI 1770790651 CMS profile 1154089

100 N Brent St Ste 301, Ventura, CA 93003

Open in the dashboard

General payments

$774,501

2,266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,161,614 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jonathan Dukes of Ventura, CA is reported in the CMS Open Payments database as having received $774,501 across 2,266 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,161,614 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $248,577 370
2024 General $77,801 340
2023 General $88,115 384
2022 General $119,847 388
2021 General $112,673 340
2020 General $51,054 186
2019 General $76,435 258

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Dukes
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Jonathan Dukes were reported at $248,577. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Jonathan Dukes Clinical Cardiac Electrophysiology median Middle half National median
2019 $76,435 $2,361 $585–$8,260 $163
2020 $51,054 $993 $247–$4,351 $114
2021 $112,673 $1,185 $326–$4,739 $132
2022 $119,847 $2,073 $554–$6,789 $149
2023 $88,115 $2,568 $759–$8,159 $160
2024 $77,801 $2,557 $703–$7,403 $164
2025 $248,577 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $253,853 582 payments
  2. Biotronik Inc. $129,358 356 payments
  3. Medical Device Business Services, Inc. $112,738 85 payments
  4. Medtronic, Inc. $110,777 428 payments
  5. Boston Scientific Corporation $84,200 363 payments
  6. Medtronic Vascular, Inc. $26,773 116 payments
  7. Pfizer Inc. $15,533 36 payments
  8. Siemens Medical Solutions USA, Inc. $11,903 9 payments
  9. Abbott Laboratories $9,740 101 payments
  10. E.R. Squibb & Sons, L.L.C. $9,164 23 payments
  11. Other $10,462 167 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $339,429 134 payments
  2. Travel and Lodging $192,304 325 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $121,468 45 payments
  4. Food and Beverage $73,168 1,735 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $41,400 18 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $6,200 3 payments
  7. Education $532 6 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $254,557 476 payments
  2. Carto 3 System $57,559 120 payments
  3. Solia $25,824 60 payments
  4. BioMonitor $24,998 61 payments
  5. Edora $21,597 55 payments
  6. Acticor $21,597 55 payments
  7. Rivacor $21,135 53 payments
  8. Acticor 7 VR-T DX $20,641 27 payments
  9. Edora 8 DR-T $19,643 20 payments
  10. Rivacor 7 DR-T $18,253 17 payments
  11. Other $191,372 1,219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

544

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$217,823

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

44.7%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 157 $182,663
Xarelto Rivaroxaban Brand 18 $17,588
Entresto Sacubitril/Valsartan Brand 11 $11,871
Propafenone Hcl Er Propafenone Hcl Brand 12 $1,067
Flecainide Acetate Generic 29 $1,056
Metoprolol Succinate Generic 58 $798
Amiodarone Hcl Generic 35 $491
Omeprazole Generic 20 $336
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 12 $330
Sotalol Sotalol Hcl Brand 16 $299

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$670,112

Medicare's payments for the services billed

Medicare patients

1,051

Average age 78

Services billed

6,853

469 women, 582 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 66%
Ischemic heart disease 50%
Arthritis 49%
Heart failure 47%
Chronic kidney disease 36%
Diabetes 34%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
$103 — —
LEQVIO
$80 — —
VYNDAQEL
$69 — —
CAMZYOS
$55 — —
ELIQUIS
$34 157 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

2,266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record